Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 9/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14075340 | 0.84 | OPRM1 (0.42) | OPRK1OPRM1OPRD1 | |
| SCHEMBL14075334 | 0.84 | OPRK1 (0.34) | OPRK1OPRM1OPRD1 | |
| SCHEMBL14075212 | 0.83 | OPRK1 (0.34) | OPRK1OPRM1OPRD1 | |
| SCHEMBL14075145 | 0.83 | OPRM1 (0.39) | OPRK1OPRM1OPRD1 | |
| SCHEMBL14075209 | 0.81 | OPRM1 (0.41) | OPRK1OPRM1OPRD1 | |
| SCHEMBL18162869 | 0.80 | HCRTR1 (0.43) | OPRK1OPRM1OPRD1ALDH1A1CYP3A4 | |
| SCHEMBL14075531 | 0.74 | OPRM1 (0.57) | OPRK1OPRM1OPRD1ALDH1A1CYP3A4 | |
| SCHEMBL13660036 | 0.74 | OPRD1 (0.30) | OPRK1OPRM1OPRD1 | |
| SCHEMBL14075329 | 0.73 | OPRM1 (0.34) | OPRK1OPRM1OPRD1 | |
| SCHEMBL18162960 | 0.72 | OPRM1 (0.46) | OPRK1OPRM1OPRD1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234306-A1 | N-Oxides of 4,5-Epoxy-Morphinanium Analogs | PROGENICS PHARMACEUTICALS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234306-A1 | N-Oxides of 4,5-Epoxy-Morphinanium Analogs | OPRM1, OPRD1, OPRK1 | OPRK1 3/4885OPRM1 1/4885OPRD1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.